Invivyd Inc. (IVVD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $171.58M
Last updated: Nov 17, 2026 at 11:05 AM ET
Invivyd Inc. (IVVD) Earnings: Report Dates and Results
Invivyd (IVVD) is expected to report earnings on Mar 1, 2027. In the quarter ended Jun 30, 2026, Invivyd reported EPS of -$0.14, above the -$0.15 estimate. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
IVVD has an expected report date of Mar 1, 2027.
IVVD Earnings Call
The latest IVVD earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 21 quarters below that had an estimate, IVVD beat 10 and missed 11. Revenue for the quarter ended Jun 30, 2026 was $14.29M, up 21.2% from $11.79M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.14 | -$0.15 | N/A | +6.67% | Beat | N/A | 1 | 0 up, 0 down | Aug 13, 2026 | $14.29M |
| Mar 31, 2026 | -$0.13 | -$0.08 | -$0.08 - -$0.08 | -62.50% | Miss | N/A | 1 | 0 up, 0 down | May 14, 2026 | $13.74M |
| Dec 31, 2025 | -$0.04 | -$0.09 | -$0.17 - -$0.03 | +54.51% | Beat | N/A | 2 | 1 up, 0 down | Mar 5, 2026 | $17.21M |
| Sep 30, 2025 | -$0.06 | -$0.09 | -$0.13 - -$0.06 | +33.33% | Beat | N/A | 2 | N/A | Nov 6, 2025 | $13.13M |
| Jun 30, 2025 | -$0.12 | $0.01 | $0.01 - $0.01 | N/A | N/A | N/A | 1 | 1 up, 0 down | Aug 14, 2025 | $11.79M |
| Mar 31, 2025 | -$0.14 | -$0.04 | N/A | -250.00% | Miss | N/A | 1 | 0 up, 1 down | May 15, 2025 | $11.30M |
| Dec 31, 2024 | -$0.15 | -$0.10 | -$0.10 - -$0.10 | -50.00% | Miss | N/A | 1 | 1 up, 0 down | Mar 20, 2025 | $13.82M |
| Sep 30, 2024 | -$0.51 | -$0.35 | -$0.35 - -$0.35 | -45.71% | Miss | N/A | 2 | 0 up, 1 down | Nov 14, 2024 | $9.30M |
| Jun 30, 2024 | -$0.40 | -$0.39 | -$0.46 - -$0.27 | -2.56% | Miss | N/A | 3 | 0 up, 0 down | Aug 14, 2024 | $2.26M |
| Mar 31, 2024 | -$0.38 | -$0.39 | -$0.57 - -$0.39 | +2.56% | Beat | N/A | 3 | 1 up, 0 down | May 9, 2024 | N/A |
| Dec 31, 2023 | -$0.67 | -$0.42 | -$0.51 - -$0.37 | -59.52% | Miss | N/A | 3 | 0 up, 0 down | Mar 28, 2024 | $3.02M |
| Sep 30, 2023 | -$0.36 | -$0.50 | -$0.55 - -$0.47 | +28.00% | Beat | N/A | 3 | 0 up, 0 down | Nov 9, 2023 | N/A |
| Jun 30, 2023 | -$0.46 | -$0.45 | N/A | -2.22% | Miss | N/A | 3 | 0 up, 0 down | Aug 10, 2023 | N/A |
| Mar 31, 2023 | -$0.32 | -$0.48 | N/A | +33.33% | Beat | N/A | 3 | 0 up, 0 down | May 11, 2023 | N/A |
| Dec 31, 2022 | -$0.25 | -$0.39 | -$0.40 - -$0.39 | +35.90% | Beat | N/A | 2 | 0 up, 0 down | Mar 23, 2023 | N/A |
| Sep 30, 2022 | -$0.42 | -$0.37 | N/A | -13.51% | Miss | N/A | 3 | 0 up, 0 down | Nov 10, 2022 | N/A |
| Jun 30, 2022 | -$0.47 | -$0.50 | N/A | +6.00% | Beat | N/A | N/A | N/A | Aug 15, 2022 | N/A |
| Mar 31, 2022 | -$0.91 | -$0.56 | N/A | -62.50% | Miss | N/A | N/A | N/A | May 13, 2022 | N/A |
| Dec 31, 2021 | -$0.77 | -$1.03 | N/A | +25.24% | Beat | N/A | N/A | N/A | Mar 30, 2022 | N/A |
| Sep 30, 2021 | -$0.89 | -$0.57 | N/A | -56.14% | Miss | N/A | N/A | N/A | Nov 15, 2021 | N/A |
| Jun 30, 2021 | -$0.18 | -$0.80 | N/A | +77.50% | Beat | N/A | N/A | N/A | Aug 6, 2021 | N/A |
| Mar 31, 2021 | -$2.14 | -$0.60 | N/A | -256.67% | Miss | N/A | N/A | N/A | Jun 2, 2021 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.36, after -$1.44 the year before. It was -$3.98 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.36 | N/A |
| Dec 31, 2024 | -$1.44 | N/A |
| Dec 31, 2023 | -$1.81 | N/A |
| Dec 31, 2022 | -$2.05 | N/A |
| Dec 31, 2021 | -$3.98 | N/A |
Earnings Calls
The 6 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 7,200 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 7,200 | 10 | |
| 2025Q4 | Dec 31, 2025 | 6,285 | 8 | |
| 2025Q3 | Sep 30, 2025 | 3,383 | 7 | |
| 2025Q1 | Mar 31, 2025 | 6,989 | 9 | |
| 2024Q3 | Sep 30, 2024 | 6,193 | 11 | |
| 2024Q2 | Jun 30, 2024 | 5,442 | 10 |
2026Q1 Earnings Call
Opening remarks
Katie Falzone Senior Vice President of Finance Thank you, Olivia. A short while ago, we issued a press release announcing our Q1 2026 financial results and recent business highlights. That press release and the slides that are being used on today's webcast can be found in the Investors section of the Invivyd website under the Press Release and Events and Presentations sections, respectively. Today's discussion will be led by Marc Elia, Chairman of Invivyd's Board of Directors. He is joined by Dr. Michael Mina, Chief Medical Officer; Dr. Robert Allen, Chief Scientific Officer; Tim Lee, Chief Commercial Officer; and Bill Duke, Chief Financial Officer. During today's discussion, we will be making forward-looking statements concerning, among other things, our corporate and commercial strategy, our research and development activities, our regulatory plans, certain financial expectations, our future prospects and other statements that are not historical facts. These forward-looking statements are covered within the meaning of the Private Securities Litigation Reform Act and are subject to various risks, assumptions and uncertainties that may change over time and cause our actual results to differ materially from those expressed or implied today. These forward-looking statements speak only as of the date of this call, and Invivyd assumes no duty to update such statements. Additional information on the risk factors that could affect Invivyd's business can be found in our filings made with the U.S. Securities and Exchange Commission, including our most recent Form 10-K, which are also available on our website. I will now turn the call over to Marc.
Marc Elia Chairman Thanks, Katie. Good morning, and thank you all for joining us. It's an exciting time for Invivyd and an exciting time for the future of infectious disease medicine. The first quarter of 2026 and the current quarter have been very busy here, and we'll use this time today to remind you of our news and put it into the broader context of our mission. I'll start by recapping some recent events. First, our pivotal program continues at high speed. As you may remember, we triggered our DECLARATION study upsizing in early April, and the recruitment speed into this additional upsized cohort occurred well faster than our internal expectations. Given the lull in COVID-19 and overall respiratory disease burden in April, we actually slowed recruitment to stretch our upsized patient exposures into what we would expect to be a normal summer COVID wave. We've resumed full speed recruitment and believe we will finish up imminently, keeping the program on time with our previous estimates. Next, we have substantially increased our government affairs activity of late, and I'll share some general observations about what we are seeing and hearing in Washington, D.C.
Frequently Asked Questions About IVVD
When is Invivyd's next earnings date?
Invivyd's next earnings report is expected for Mar 1, 2027.
Did IVVD beat earnings estimates last quarter?
Yes. Invivyd reported EPS of -$0.14 for the quarter ended Jun 30, 2026, above the -$0.15 estimate, a 6.67% surprise.
What EPS do analysts expect from IVVD next quarter?
The consensus EPS estimate for Invivyd for the quarter ending Dec 31, 2026 is -$0.13 from 5 analysts, with estimates from -$0.15 to -$0.08.
How often does IVVD beat earnings estimates?
Invivyd beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of -39.53%.
IVVD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors